Showing 16 results
Dr Munkley will investigate why the loss of sugar groups on the outside of the cell leads to prostate cancer cell death, and whether she can use existing anti-glycosylation drugs to exploit this as a potential new treatment for aggressive prostate cancer.
This team of PhD and clinical scientists aims to postpone surgery by reprogramming immune cells in the prostate to prevent cancers growing back after primary treatment.
Our first Travelling Prize Fellow will be working with a team in Rotterdam to develop the skills to further develop promising drugs for treating prostate cancer.
Funded research by Dr Luke Gaughan of Newcastle University which looks to understand how different forms of the androgen receptor are regulated in advanced prostate cancer.
Funded research by Dr Ananya Choudhury of the University of Manchester which looks to identify patients with low oxygen (hypoxic) prostate cancers. This will allow doctors to select patients who are most likely to benefit from appropriate radiotherapy.
Funded research by Prof. Norman Maitland at the University of York into the loss of latexin and its relationship to aggressive cancer.
Funded research by Professor David Elliott of University of Newcastle into understanding how male hormone testosterone controls the growth of prostate cancer cells.
Funded research by Dr Kelly Coffey of Newcastle University into why hormone therapy resistance occurs, and what happens to certain proteins when prostate cancer cells stop responding to hormone therapy.
Funded research by Dr. Craig Robson of Newcastle University into the androgen receptor protein and its implications for resistance to hormone therapy.
Funded research by Dr. Anne Collins of York University into the effect of blocking the stat3 protein in cells from men with prostate cancer rather than lab-grown cells.
Funded research by Professor Craig Robson of Newcastle University into what happens to androgen receptor expression under hormone therapy, using new models which mimic the environment of advanced prostate cancers.
Funded research by Professor David Elliott of Newcastle University into the effect of androgen on gene expression in prostate cancer cells, how the affected genes influence progression and whether this basis can be used to diagnose different types of the disease.
Funded research by Prof. Craig Robson of Newcastle University into phosphatases, their effect on androgen receptors and their potential for use as a drug target.
Funded research by Dr Mark Coles of York University into the stroma cells that surround tumours, what happens to them during tumour spread, and whether affecting them can provide a means of preventing metastasis.